BioSpace News Archive

QMC HealthID, a wholly owned subsidiary of Quantum Materials Corp, today announced that it has partnered with Tried & Tested COVID-19 testing services.

Elicio Therapeutics, a private biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph-node targeting Amphiphile technology, announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for ELI-002. ELI-002 is an Amphiphile

U.S. Stem Cell, Inc. (OTC PINK:USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce the efforts of NorthStar Biotech Group and USRM Board Members to reinvest in U.S. Stem Cell, Inc.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced an expansion of its collaboration with Labcorp

IASO Biotherapeutics (IASO Bio) and Innovent Biologics, Inc. (Innovent, HKEX: 01801), today jointly announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for CT103A, an investigational chimeric antigen receptor (CAR)-T cell therapy co-developed by IASO Bio and Innovent (IASO Bio: CT103A, Innovent: IBI326)

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has begun selling its CompuFlo® Epidural Instrument and related disposables to the University Hospital of Würzburg , one of the leading national hospitals in Germany. Dr. Peter Kranke, Professor of Anesthesia in the Department of Anesthesia

MiRus announced that they will offer a LIFETIME LIMITED WARRANTY on its Molybdenum-Rhenium superalloy rod technology.

Sanofi Canada announced today that Health Canada has approved DUPIXENT® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis (AD) in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.3

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath announced a partnership today that will further empower the I-SPY platform trials with robust, streamlined technology infrastructure to drive the ease and efficiency of trial execution.

The healthcare data interoperability market is expected to be driven by increasing spending on healthcare across developed as well as developing countries.